“Advances in scientific knowledge and drug development technology have provided an opportunity for new approaches to drug development, including the development of drugs for the treatment of rare diseases,’ said Patrizia Cavazzoni M.D., Acting Director of the U.S. FDA’s Center for Drug Evaluation and Research.
“In fact, in the past eight years, the FDA has approved more than twice as many drugs for rare diseases, often referred to as orphan drugs, as in the previous eight years.”
Excerpts from Dr. Cavazzoni’s press statement on January 4, 2021, are inserted below.
Read More
